肝癌DSA血供类型与经肝动脉灌注^(131)Ⅰ-HAb18F(ab')_2治疗后瘤体大小变化的关系探讨  

Hepatic intraarterial^(131)Ⅰ-HAb18F(ab')_2 radioimmunotherapy on PLC with different types of blood supply through DSA

作　　者：吴少平[1] 卢武胜[2] 徐大伟 郑志勇[2] 

机构地区：[1]成都医学院第一附属医院放射科,610500 [2]四川大学华西医院普外科 [3]北京武警总队医院放射科

出　　处：《介入放射学杂志》2007年第4期243-245,共3页Journal of Interventional Radiology

摘　　要：目的探讨不同血供类型的原发性肝癌(简称肝癌)经肝动脉灌注131Ⅰ-HAb18F(ab')2的疗效差异。方法使用Seldinger技术,超选择性肝动脉插管灌注0.75mCi/kg131Ⅰ-HAb18F(ab')2注射液,CT随访治疗前后的瘤体大小变化。按照DSA造影表现,将30例患者分为多、中等、少血供3型,分析不同类型患者瘤体缩小的差异。结果DSA显示多、中等血供型肝癌肿瘤缩小的比率分别为60%、37.5%,2例少血供型肝癌治疗后1例瘤体显著缩小。结论131Ⅰ-HAb18F(ab')2免疫内照射治疗对不同血供类型的肝癌均有一定的缩小瘤体的效果。Objective To study the possible different effects on primary liver cancer of various types of blood supply demonstrated by DSA via hepatic artery radioimmunotherapy with ^131 Ⅰ -HAb18F（ab＇）2. Methods Under thyroid protection and negative dermal sensitivity test, 46 times of intraarterial injection with a 0.75 mCi/kg dose of 13l I labeled murine HCC monoclonal antibody fragment [HAb18F（ab＇）2] were performed in 30 patients of PLC using the Seldinger technique. The shrinkage rates of tumor volume were analyzed according to hyper, moderate and hypo vascular three types provided by DSA. Results The volume shrinkage rates of hyper and moderate vascular HCC were 60% and 37.5% respectively, while that of 2 cases of hypovascular HCC showed significantly reduction. Conclusion ^131 Ⅰ-HAblSF（ab＇）2 internal radioimmunotherapy prossesses certain signification volume shrinkage efficacy on different blood supplies provided by DSA. （J Intervent Radiol, 2007, 16 ： 243-245）

关 键 词：肝癌 数字减影血管造影术 ^131 Ⅰ—HAb18 放射免疫治疗 肝动脉 

分 类 号：R735.7[医药卫生—肿瘤]